Want to see CCLD full AI Analyst Report?
Top Page
CareCloud
(NASDAQ:CCLD)
Select Model
Select Model
Rating:68Neutral
Price Target:
$3.00
▲(35.14% Upside)
Action:Reiterated
Date:08/06/26
CCLD scores as moderately attractive primarily due to improving profitability and strong cash flow, reinforced by reaffirmed guidance and solid year-over-year growth with a higher recurring revenue mix. The score is held back by balance-sheet volatility and execution risk tied to a stronger second-half outlook, while valuation (P/E ~30.65 with no dividend yield) limits upside appeal despite improving technical momentum.
Positive Factors
High recurring revenue mix
A ~75% recurring technology-enabled mix and sizable YoY recurring revenue growth improve revenue predictability and customer retention. Durable subscription cash flows support long-term planning, reduce top-line volatility, and create a reliable base for cross-selling higher‑margin services over time.
Negative Factors
Balance-sheet volatility
Rising debt and materially lower equity increase financial sensitivity to operational swings or accounting changes. Reduced capital cushion can limit strategic flexibility, raise borrowing costs or covenant risk under stress, and heighten the consequences of execution missteps over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High recurring revenue mix
A ~75% recurring technology-enabled mix and sizable YoY recurring revenue growth improve revenue predictability and customer retention. Durable subscription cash flows support long-term planning, reduce top-line volatility, and create a reliable base for cross-selling higher‑margin services over time.
Read all positive factors
CareCloud (CCLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$110.06M
Dividend YieldN/A
Average Volume (3M)199.58K
Price to Earnings (P/E)37.1
Beta (1Y)1.90
Revenue Growth15.07%
EPS GrowthN/A
CountryUS
Employees3,650
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.07
Shares Outstanding42,493,860
10 Day Avg. Volume164,695
30 Day Avg. Volume199,584
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)2.08
Price to Sales (P/S)1.03
P/FCF Ratio6.03
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.25Price Target Upside136.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.21
Revenue Forecast (FY)$131.25M
CareCloud Business Overview & Revenue Model
Company Description
CareCloud, Inc. operates as a specialized healthcare technology firm, delivering a comprehensive portfolio of cloud-powered solutions and related professional services. Its primary clientele consists of medical providers and hospitals throughout t...
How the Company Makes Money
CareCloud primarily generates revenue by selling software and services to healthcare providers. Key revenue streams typically include: (1) subscription and usage-based fees for its cloud software products (e.g., practice management and EHR platfor...
CareCloud Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call presents a constructive, strategic story: solid top-line growth (+16% Q2, +15% H1), a growing recurring revenue mix, continued GAAP profitability streak, a cleaner capital structure after fully redeeming Series B, and clear progress on AI and a new compliance SaaS initiative. Near-term reported profitability and some cash metrics are pressured by deliberate investment choices — accelerated R&D expense, acquisition-related amortization, and higher interest — and by integration work (notably Medsphere). Management reaffirmed guidance and expects a stronger second half as investments convert to scale. Overall, positives (revenue/regional trends, recurring revenue expansion, capital structure improvement, AI/product milestones, new market entry) outweigh the near-term headwinds driven by strategic investments and integration costs, but execution risk remains.Positive Updates
Revenue Growth and Recurring Revenue Expansion
Q2 revenue was $31.9M, up 16% YoY (from $27.4M); first half revenue was $63.2M, up 15% YoY (from $55.0M). Recurring technology-enabled revenue represented ~75% of Q2 revenue (up from 69% a year ago, +6 percentage points) with recurring revenue of ~$24M in the quarter (approximately +$5M YoY, roughly +26%).
Negative Updates
Near-Term Profitability Pressure from Strategic Investments
Q2 GAAP net income declined to $1.1M from $2.9M a year ago (≈-62% YoY). Year-to-date GAAP net income declined to $2.0M from $4.9M (≈-59%). Management attributes declines to intentional investments: doubled R&D expense (more expensed vs. capitalized), acquisition integration and amortization, and higher interest expense.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Recurring Revenue Expansion
Q2 revenue was $31.9M, up 16% YoY (from $27.4M); first half revenue was $63.2M, up 15% YoY (from $55.0M). Recurring technology-enabled revenue represented ~75% of Q2 revenue (up from 69% a year ago, +6 percentage points) with recurring revenue of ~$24M in the quarter (approximately +$5M YoY, roughly +26%).
Read all positive updates
Company Guidance
CareCloud reaffirmed full‑year 2026 guidance of $128.0–$132.0 million in revenue, $29–$31 million of adjusted EBITDA, and GAAP EPS of $0.20–$0.23. In the first half the company reported $63.2 million of revenue (Q2 revenue $31.9M, +16% YoY), recurring technology‑enabled revenue of about $24.0M in Q2 (~75% of revenue), GAAP net income of $2.0M YTD ($1.1M in Q2), adjusted EBITDA of $11.3M YTD ($5.9M in Q2), adjusted net income of $4.5M YTD ($2.4M or $0.06/share in Q2) and $8.1M of free cash flow YTD. The guidance implies a materially stronger second half (roughly $64.8–$68.8M of revenue remaining, or about $32.4–$34.4M per quarter, and about $17.7–$19.7M of adjusted EBITDA needed in H2), benefits from the May 15 redemption of Series B (eliminating ~$3.3M of annual preferred dividends starting Q3 and funded by a $50M credit facility), and a balance sheet with ~$13.4M cash, ~$695K net working capital and a $60M ATM; achievement remains contingent on client signings, project timing and integration/expense execution.CareCloud Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
64
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 128.64M | 120.50M | 110.84M | 117.06M | 138.83M | 139.60M |
| Gross Profit | 40.82M | 56.04M | 49.99M | 46.24M | 54.39M | 52.68M |
| EBITDA | 27.61M | 28.26M | 25.05M | -31.29M | 21.02M | 19.70M |
| Net Income | 7.99M | 10.80M | 7.85M | -48.67M | 5.43M | 2.84M |
Balance Sheet | ||||||
| Total Assets | 93.85M | 87.60M | 71.61M | 77.83M | 136.17M | 140.85M |
| Cash, Cash Equivalents and Short-Term Investments | 13.39M | 3.12M | 5.14M | 3.33M | 12.30M | 9.34M |
| Total Debt | 54.01M | 4.28M | 3.47M | 14.73M | 13.81M | 16.87M |
| Total Liabilities | 76.45M | 28.09M | 21.84M | 36.11M | 34.48M | 42.92M |
| Stockholders Equity | 17.40M | 59.51M | 49.77M | 41.72M | 101.69M | 97.93M |
Cash Flow | ||||||
| Free Cash Flow | 27.57M | 20.53M | 18.95M | 3.85M | 9.38M | 2.77M |
| Operating Cash Flow | 26.72M | 28.56M | 20.64M | 15.46M | 21.15M | 13.33M |
| Investing Cash Flow | -24.27M | -24.54M | -7.41M | -11.61M | -11.77M | -23.15M |
| Financing Cash Flow | 407.00K | -5.61M | -11.26M | -13.29M | -7.65M | -519.00K |
CareCloud Technical Analysis
Positive
2.22
Price Trends
2.31
Positive
2.57
Positive
2.75
Negative
Market Momentum
0.06
Negative
58.45
Neutral
67.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCLD, the sentiment is Positive. The current price of 2.22 is below the 20-day moving average (MA) of 2.40, below the 50-day MA of 2.31, and below the 200-day MA of 2.75, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 58.45 is Neutral, neither overbought nor oversold. The STOCH value of 67.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCLD.
CareCloud Risk Analysis
CareCloud disclosed 73 risk factors in its most recent earnings report. CareCloud reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CareCloud Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $759.05M | 80.68 | 2.79% | ― | 14.05% | ― | |
70 Outperform | $4.75B | 34.42 | 3.59% | ― | 19.23% | 44.44% | |
68 Neutral | $110.06M | 37.11 | 16.56% | ― | 15.07% | ― | |
60 Neutral | $139.22M | -0.50 | -129.70% | ― | -7.54% | -143.41% | |
55 Neutral | $211.76M | -2.61 | -33.27% | ― | -19.00% | 40.98% | |
52 Neutral | $529.12M | -1.04 | -99.16% | ― | -4.50% | -184.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CCLD
CareCloud
2.59
-0.13
-4.78%
EVH
Evolent Health
4.68
-4.34
-48.12%
PHR
Phreesia
12.28
-16.82
-57.80%
HCAT
Health Catalyst
1.85
-1.15
-38.33%
AMWL
American Well
12.45
5.20
71.72%
WAY
Waystar Holding Corp.
24.78
-11.50
-31.70%
CareCloud Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
CareCloud Delivers Q2 Revenue Growth Amid AI Investments
Positive
Aug 6, 2026
CareCloud reported its second-quarter 2026 results on August 6, 2026, posting 16% year-over-year revenue growth to $31.9 million and its ninth consecutive quarter of positive GAAP net income, though profits and adjusted EBITDA declined versus the ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
CareCloud Amends Credit Agreement to Refine Financing Terms
Neutral
Jun 26, 2026
On June 25, 2026, CareCloud, Inc. disclosed that it entered into a First Amendment to its Credit Agreement with Citizens Bank, N.A., effective as of May 6, 2026, adjusting certain post-closing obligations and conditions tied to its financing arran...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
CareCloud Shareholders Approve 2026 Equity Incentive Plan
Positive
Jun 5, 2026
At its June 4, 2026 annual meeting in Somerset, N.J., CareCloud shareholders approved a 2026 Equity Incentive Plan authorizing up to 1,000,000 new shares of common stock, following prior board approval. The plan is intended to support equity-based...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
CareCloud fully redeems and delists Series B preferred
Neutral
May 15, 2026
CareCloud, Inc. redeemed and delisted its 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock in May 2026, while keeping its common stock listed on the Nasdaq Global Market under the symbol CCLD. The Series B preferred shares were delis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.